newsfilter
← Latest News
Business Wire·

bioAffinity Technologies and AvMEDICAL Announce Nationwide Federal Healthcare Distribution Agreement for CyPath® Lung

  • bioAffinity Technologies has entered a distribution agreement with AvMEDICAL, a Service-Disabled Veteran-Owned Small Business (SDVOSB), to market CyPath Lung to federal healthcare agencies including VA medical centers.
  • AvMEDICAL's national sales force will leverage established government procurement channels, including IDIQ contracts, to expand bioAffinity's commercial reach within the government healthcare supply chain.
  • The partnership aims to simplify procurement processes & increase access to CyPath Lung for veterans, addressing the high priority of lung cancer detection in VA systems where nearly 8,000 veterans are diagnosed annually.
  • CyPath Lung is a noninvasive Laboratory Developed Test (LDT) utilizing flow cytometry & AI to detect lung cancer in patients with indeterminate pulmonary nodules, demonstrating 92% sensitivity & 87% specificity in clinical trials.
  • The test is performed by Precision Pathology Laboratory Services, a CLIA-certified subsidiary of bioAffinity, & is intended to be used alongside other diagnostic tools rather than as a sole diagnostic method.
  • AvMEDICAL will develop co-branded marketing materials & actively promote the technology to federal customers to improve patient outcomes for veterans & active-duty military personnel.